Page 41 - AAOMP Meeting 2019

POSTER ABSTRACTS - TUESDAY, JUNE 11, 2019

#33 MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) AS A POTENTIAL ORAL
MUCOSITIS BIOMARKER.
Dr. Ana Carolina Prado Ribeiro (Dental Oncology Service, Cancer Institute of Sao Paulo State (ICESP), Faculty of
Medicine, Sao Paulo University (USP)), Ms. Natalia Palmier (University of Campinas (UNICAMP)), Ms. Tatiane de
Rossi (Brazilian Biosciences National Laboratory (LNBio-CNPEM)), Dr. Adriana Paes-Leme (Brazilian Biosciences
National Laboratory (LNBio-CNPEM)), Dr. Karina Morais-Faria (ICESP), Prof. Cesar Migliorati (College of
Dentistry, University of Florida, Gainesville), Dr. Thais Brandao (Dental Oncology Service, Cancer Institute of Sao
Paulo State (ICESP), Faculty of Medicine, Sao Paulo University (USP)), Dr. Alan Santos-Silva (University of
Campinas (UNICAMP), Piracicaba, São Paulo, Brazil)
Introduction: This study aimed to characterize the salivary proteomic profile of patients treated for oral
squamous cell carcinoma (OSCC) and to further correlate it with the risk of developing severe radiation-
related oral mucositis (OM).Material and methods: 41 OSCC patients submitted to adjuvant radiotherapy
(RT) or chemoradiotherapy (CRT) were included in this study. OM and OM-related pain were daily
evaluated during RT and graded according to the Common Toxicity Criteria for Adverse Events(NCI,
Version4.0, 2010) and the Visual Analogue Scale (VAS). For the molecular analysis, whole saliva was
collected immediately prior to RT and subjected to proteomic by means of liquid chromatography coupled to
mass spectrometry (LC-MS/MS) (LTQ Orbitrap Velos MS/ Thermo Fisher Scientific, Bremen, Germany) and
label-free protein quantification. The results obtained from the targeted proteomic analysis were compared to
OM clinical outcomes. Statistical analysis was performed using the Wilcoxon test. Results:58% of the
patients were submitted to CRT protocols with a mean RT dose of 66Gy; 44% of the patients presented grade
2 and 32% presented grade 3 as highest OM grade during RT, with a mean highest reported VAS of 3.53. For
the target proteomics analysis, a total of 65 proteins were observed mostly related to biological processes,
such as immune responses, peptidase inhibitor activity, and inflammatory system. The Macrophage migration
inhibitory factor (MIF HUMAN) was statistically significant when correlated to OM grade. MIF was observed
in higher abundance for OM grades 3/4 when compared to grades 1/2 (p=0.04). Conclusions: This seems to
be the first study to describe MIF as a potential salivary marker of high-grade OM in OSCC patients.
Additional future studies are needed to validate these results and to better understand the role of MIF in the
pathogenesis of OM.

#34 IS PHOTOBIOMODULATION THERAPY USE FOR PREVENTION AND TREATMENT
OF TOXICITIES INDUCED BY CANCER TREATMENT SAFE? A SYSTEMATIC REVIEW.
Dr. Alan Santos-Silva (University of Campinas (UNICAMP), Piracicaba, São Paulo, Brazil), Ms. Mariana Paglioni
(University of Campinas (UNICAMP)), Ms. Anna Luiza Araújo (University of Campinas (UNICAMP)), Ms. Paola
Arboleda (UNICAMP), Ms. Natalia Palmier (University of Campinas (UNICAMP)), Dr. Karina Morais-Faria
(ICESP), Mr. Felipe Martins (University of Campinas (UNICAMP)), Dr. Ana Carolina Prado-Ribeiro (Cancer
Institute of Sao Paulo State (ICESP), Faculty of Medicine, Sao Paulo University (USP)), Dr. Manoela Martins
(Federal University of Rio Grande do Sul (UFRGS)), Prof. Marcio Lopes (University of Campinas (UNICAMP)), Dr.
Adriana Paes-Leme (Brazilian Biosciences National Laboratory (LNBio-CNPEM)), Prof. Cesar Migliorati (College
of Dentistry, University of Florida, Gainesville), Dr. Thais Brandao (Dental Oncology Service, Cancer Institute of
Sao Paulo State (ICESP), Faculty of Medicine, Sao Paulo University (USP))
Introduction: Photobiomodulation therapy (PBMT) also known as low-level laser therapy has been
increasingly used for the treatment of toxicities related to cancer treatment. One of the challenges for the
universal acceptance of PBMT use in cancer patients is whether or not there is a potential for the light to
stimulate the growth of residual malignant cells that evaded oncologic treatment, increasing the risk for
tumor recurrences and the development of second primary tumors. Current science suggests promising
effects of PBMT in the prevention and treatment of oral mucositis and breast cancer-related lymphedema
among other cancer treatment toxicities. Nevertheless, this seems to be the first systematic review to analyze
the safety of the use of PBMT for the treatment of cancer-related toxicities. Material and methods: This
study aimed to evaluate the current literature regarding the safety of PBMT use in the prevention and/or
treatment of complications related to antineoplastic therapies. Scopus, MEDLINE/PubMed, and Embase
were searched electronically. The protocol for this systematic review was registered in the International
Prospective Register of Systematic Review (PROSPERO) database (registration number CRD42018094364)
to avoid duplicate publications of systematic reviews and to enable comparison among methods as they
are reported in the review protocol. Results: A total of 27 articles met the search criteria. Selected studies
included the use of PBMT for prevention and treatment of oral mucositis, lymphedema, radiodermatitis,
and peripheral neuropathy. Most studies showed that no adverse events were observed with the use of
PBMT. Conclusions: The results of this systematic review, based on current literature, suggest that the use
of PBMT in the prevention and treatment of cancer treatment toxicities does not lead to the development
of safety issues.